Death in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Year 2005: Percentage Breakdown by Cause of death -Heart Diseases, Cancer, Cerebrovascular ... Graph/Chart) II-17 Table 11: Cancer death Rates in the US (2007): Percentage Breakdown ... Year 2005: Percentage Breakdown by Cause of death -Heart Diseases, Cancer, Cerebrovascular ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... 0.61, representing a 39% lower rate of death for patients treated with OGX-011. 3) A ... Patients treated with OGX-011 had a rate of death 51% lower than patients treated with ... analyses found that the lower rate of death was associated with the effect of OGX-011 ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... discontinuation of treatment and in rare cases of death DOXIL may potentiate ... Patients experienced greater risks for death and serious cardiovascular events when ... renal failure experienced greater risks for death and serious cardiovascular events (including ...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

... of biopsy proven acute rejection, graft failure, death and/or lost to follow-up at 12 months in the ... biopsy proven acute rejection (BPAR), graft loss, death and/or lost to follow-up in comparison to each of ... sirolimus (38.1%) groups. Graft loss excluding death was also lowest in the low-dose Prograf group ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... 0.60, representing a 40% reduction in the rate of death for patients treated with OGX-011. New data ... patients treated with OGX-011 had a rate of death 46% lower than patients treated with docetaxel ... Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. ...

Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development

... He is also Director of the Apoptosis and Cell death Research Program. Dr. Salvesen earned his Ph.D. ... central role enzyme pathways play in the life and death of cells. When death pathways slow down in cells that are normally ...

Heart Disease: An Epidemic For Firefighters

... of first responders at risk of suffering sudden death or other significant cardiac events. ... environment as the primary determinants for early death in our country's first responders." Dr. ... by Fire Chief Steve Rolader, following the sudden death of one of his firefighters from cardiac arrest ...

Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)

... that most likely leads to sudden unexplainable death in epileptic patients during seizure. Victhom ... and device aimed at preventing sudden unexpected death in epilepsy (SUDEP) using its neuromodulation ... which is currently in clinical trials. "The death rate among epileptics is about three times that ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... disability and the third leading cause of death in the United States. Ultrasound scanning of the ... aortic aneurysms -- the 10th leading cause of death in men over age 50 in the United States. -- ... the age of 50 has PAD. The two leading causes of death in the developed world are heart disease and ...

Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules

... Against the Leading Vaccine-Preventable Cause of death in Young Children Worldwide Wyeth today ... is the leading vaccine-preventable cause of death in children younger than five years of age ... and adults and is a leading cause of illness and death worldwide.(6) Pneumococcal disease is caused ...

ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China

... beginning an inexorable clinical progression to death over a 6 to 24 months period. vCJD first appeared ... in their brains and other nervous tissues. The death of neurons gives a sponge-like appearance to the ... ("TRALI"), being the most common cause of death in transfusion medicine, has been ...

First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA

... the TCH regimen with 34% reduction in the risk of death (HR=0.66, 95% CI [0.47-0.93], p=0.0182) compared ... associated with a 42% reduction in the risk of death (HR=0.58, 95% CI [0.40-0.83], p=0.0024) compared ... the TCH regimen with 34% reduction in the risk of death (HR=0.66, 95% CI [0.47-0.93], p=0.0182) compared ...

Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke

... cardiovascular (CV) events. The overall death rate is 4.45%, with 3.23% of these CV deaths from ... (5.9%). The risk of stroke, MI and CV death at two years was 11.5% for the total CVD ... the incidence rates of MI and nonstroke vascular death are only about 1% per year, the risk rises in ...

Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research

... at Bionovo, the ability of BN107 to induce death cancer cell death is distinct from that of BN108. BN107 induces ... breast cancer cells. BN108 induces cancer cell death by rapid inactivation of both AKT and mTOR ...

Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems

... intended to cool patients in order to reduce cell death and damage caused by ischemic events in which ... to protect endangered cells, prevent tissue death and preserve organ function following acute ... cool the body in order to reduce cell death and damage following acute ischemic events such ...

Device That Clears Debris From Artery Aids Blood Flow in PCI

... of heart function reduced, and the risk of death higher. In an attempt to improve myocardial ... the degree of myocardial reperfusion. The rate of death in patients with a myocardial blush grade of 0/1, ... attack, repeat procedure in the target artery and death in patients with a myocardial blush grade of 0/1, ...

Historic Breakthrough in Fighting Children's Batten Disease as China Stem Cells Give New Lease on Life to 6 Year Old California Boy

... of sight and motor skills until shortly before death they become blind, bedridden, suffer ... This form progresses rapidly and always ends in death sometime between ages 8 and 12. The typical early ... belief in global medical circles that premature death from this life-limiting disease is ...

Vasogen's Research Published in European Journal of Neuroscience

... factors that result in the death of nerve cells in an area of the brain called the ... with inflammatory processes that lead to the death of certain nerve cells, the dopaminergic neurons, ... including cytokines, leading to the death of nerve cells and the eventual loss of ...

Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration

... heart attack, non-fatal stroke and cardiovascular death in 13,608 patients. In the study, treatment ... attack, non-fatal stroke or cardiovascular death (p -- 52 percent reduction compared with ... bleeding (1.3% vs. 0.8%, respectively). death from cardiovascular causes (2% vs. 2.2%, ...

Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy

... receptor 1, a protein involved in programmed cell death (apoptosis). The first randomized Phase 2 trial ... binds TRAIL receptor 1 and triggers NSCLC cell death through apoptosis; and (3) HGS- ETR1 inhibits ... It is currently the leading cause of cancer death in the U.S. in both men and women. About ...

Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator

... rhythm management device to treat sudden cardiac death (SCD). The CONFIENT ICD, with an enhanced AV ... at risk of sudden cardiac death." Sudden cardiac death is the abrupt loss of heart function, usually ... fibrillation. Each year, sudden cardiac death claims the lives of as many as 350,000 people in ...

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome

... at one year, the primary endpoint of death or nonfatal myocardial infarction remained ... 17.0% p-0.01). Net clinical benefit (all cause of death / nonfatal MI / nonfatal disabling stroke) was ... follow up shows that the composite of all cause death at 1 year and major bleeding was 3.1% for ...

OncoGenex Reports Second Quarter 2009 Financial Results

... The unadjusted hazard ratio (HR), a measure used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate of death for patients treated with OGX-011. - Preliminary results of a ...

Sunesis Reports Financial Results for the Second Quarter 2009

... In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. ...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

... the unadjusted hazard ratio (HR), a measure used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate of death for patients treated with OGX-011. About OGX-011 OGX-011 is ...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... artery or low blood oxygen from anemia Type 3: Sudden cardiac death with evidence of a heart attack Type 4: Heart attacks related to a ... heart disease, which can result in ACS, is the single most common cause of death in the European Union, accounting for more than 741,000 deaths in the EU ...

PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration

... an effective treatment for SMA, the most common genetic cause of death among infants and toddlers." About PTC Therapeutics, Inc. PTC is ... atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve ...

BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management

... reduce mortality. For example, ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of cancer death in women. An estimated 22,000 new cases occur annually in the United ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... an orally-active, small molecule drug designed to promote programmed cell death (apoptosis) in tumor cells by blocking the activity of at least three ... that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small ...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

... In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. ...

Dendreon Reports Fourth Quarter and 2008 Year End Financial Results

... (IDMC) reported to Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% ... expected by the end of April. The 20 percent reduction in the risk of death that we saw in the PROVENGE arm at our interim analysis is encouraging to ...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

... In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. ...

Kidneys for Transplant Function Earlier and Last Longer When Preserved in a Machine Compared to the Traditional Box of Ice

... whose organs are removed for transplantation. Donors after cardiac death (DCD) - organ donors who have been declared dead because their heart has ... Expanded criteria donors (ECD) - brain dead donors or donors after cardiac death over the age of 60 years, or between 50 and 60 years with additional ...

Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors

... nucleoli of cancer cells, thereby selectively inducing apoptotic cell death in cancers," said Dr. William Rice, President and Chief Executive Officer ... cancer cells. As a result, quarfloxin selectively induces apoptotic cell death in cancers. Many commercialized cancer therapeutics act indirectly on rRNA ...

Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium

... of Cancer Research at Bionovo, the ability of BN107 to induce cancer cell death is distinct. BN107 induces apoptosis through the mitochondrial pathway. BN107 induces death only in estrogen receptor negative breast cancer cells. Our studies show ...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

... and physicians, since thrombosis is the leading cause of premature death in PNH and the most feared complication of the disease." Pulmonary ... Martin et al. N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of death in Sickle Cell Disease. JAMA. 2006;296(3):310. (3) Hill A, Platts ...

Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami

... ICU through high-speed wireless technology can help lower the preventable death rate by speeding up the delivery of trauma care during the 'golden hour,' ... adults and children. The center is geared toward lowering the preventable death rate by speeding up the delivery of trauma care during the "golden hour," ...

Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association

... for three years to track heart attack (myocardial infarction), stroke and death (cardiovascular and all cause). The study included 708 individuals with ... (HbA1c, duration), over the next three years, cardiovascular death was five-fold higher in the Hp 2-2 group (p=0.0001) and non-fatal MI ...

Dendreon Reports Third Quarter 2008 Financial Results

... (IDMC) reported to Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% ... for us. We were encouraged to see a 20 percent reduction in the risk of death in the PROVENGE arm versus placebo at the time of this analysis in a ...

Aposense Receives Frost & Sullivan Technology Innovation of the Year Award

... equipment or methods." While there are a few other probes for cell death in vitro in cell culture, Aposense(R) ML-10 is the only agent currently available for the clinical detection of 'cell death in the living body'. Limitations of other investigated probes include ...